Found: 9
Select item for more details and to access through your institution.
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
- Published in:
- Brazilian Journal of Infectious Diseases, 2023, v. 27, n. 3, p. 1, doi. 10.1016/j.bjid.2023.102775
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico—SMART 2017–2021.
- Published in:
- JAC-Antimicrobial Resistance, 2024, v. 6, n. 3, p. 1, doi. 10.1093/jacamr/dlae077
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates—SMART United States 2019–21.
- Published in:
- JAC-Antimicrobial Resistance, 2024, v. 6, n. 1, p. 1, doi. 10.1093/jacamr/dlad152
- By:
- Publication type:
- Article
Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents—SMART 2018–21.
- Published in:
- JAC-Antimicrobial Resistance, 2024, v. 6, n. 1, p. 1, doi. 10.1093/jacamr/dlad149
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)--SMART 2017-21.
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 4, p. 1, doi. 10.1093/jacamr/dlad098
- By:
- Publication type:
- Article
Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam--SMART 2016-21.
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 3, p. 1, doi. 10.1093/jacamr/dlad080
- By:
- Publication type:
- Article
In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 1, p. 1, doi. 10.1093/jacamr/dlad003
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2024, v. 43, n. 7, p. 1343, doi. 10.1007/s10096-024-04756-4
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2023, v. 42, n. 3, p. 365, doi. 10.1007/s10096-023-04549-1
- By:
- Publication type:
- Article